Key facts
- This page summarizes Jonathan Young's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Jan 2023, 16:56.
Jonathan Young - 03 Jan 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- AKRO
- Reported as of
- 03 Jan 2023
- Net transaction value
- -$474,163
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2023, 16:56:15 UTC
- Prior SEC filing
- 28 Dec 2022
- Next SEC filing
- 14 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Young
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Young filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 05 Jan 2023.
Change
- Previous filing in this sequence was filed on 28 Dec 2022.
- Current net transaction value: -$474,163.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKRO
transaction
Common Stock
Options Exercise
- Transaction value
- $5,398
- Shares
- +8,777
- Change %
- +4.7%
- Price
- $0.6150*
- Shares after
- 193,688
- Date
- 03 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2
AKRO
transaction
Common Stock
Sale
- Transaction value
- $479,560
- Shares
- -8,777
- Change %
- -4.5%
- Price
- $54.64
- Shares after
- 184,911
- Date
- 03 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3
AKRO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,000
- Date
- 03 Jan 2023
- Ownership
- By EA Irrevocable Trust
- Footnotes
- F4
AKRO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,000
- Date
- 03 Jan 2023
- Ownership
- By CM Irrevocable Trust
- Footnotes
- F4
AKRO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,000
- Date
- 03 Jan 2023
- Ownership
- By JL Irrevocable Trust
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKRO
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -8,777
- Change %
- -9.5%
- Price
- $0.000000
- Shares after
- 83,321
- Date
- 03 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,777
- Exercise price
- $0.6150
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 9, 2021, previously adopted by the reporting person.
Footnote F2
Includes 2,462 shares that were acquired on December 30, 2022 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Footnote F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.50 to $54.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
Footnote F4
These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Footnote F5
The options are vested and currently exercisable.